Walter Faggett Ii
Addiction Medicine · Washington, DCNPI 1316126626
Payments from drug & device makers
Across 774 payments — averaging $2228.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$459K
- Merck$421K
- Alnylam Pharmaceuticals Inc.$393K
- Modernatx, Inc.$258K
- GSK$85K
- AbbVie$57K
- plus $51K from 3 others
What the payments were for
- Food & beverage$260100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 116 | $458,631 |
| Merck | 13 | $421,201 |
| Alnylam Pharmaceuticals Inc. | 466 | $392,982 |
| Modernatx, Inc. | 116 | $258,307 |
| GSK | 32 | $85,440 |
| AbbVie(2 entities) | 20 | $56,966 |
| Genentech, Inc. | 8 | $26,335 |
| Ultragenyx Pharmaceutical Inc. | 2 | $24,702 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
How this compares
Too few addiction medicine providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Other addiction medicine in Washington
- John DombrowskiWashington$3K
- Charles GantWashington$3K
- Homaira AhadWashington$276
- Cynthia CudjoeWashington$21
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.